Inhibikase Therapeutics (Nasdaq:IKT) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IKT 주식 개요

임상 단계의 제약 회사인 인히비카제 테라퓨틱스는 파킨슨병 및 관련 질환 치료제를 개발하는 회사입니다.

IKT 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 99.5% 에서 거래

위험 분석

최근 3개월간 주가 변동폭 심해

수익이 1백만 달러 미만인 경우 ( $196K )

의미 있는 시가총액이 없습니다. ( $10M )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

+ 1 더 많은 위험

Inhibikase Therapeutics, Inc. 경쟁사

Longeveron

NasdaqCM:LGVN

US$10.2m

SAB Biotherapeutics

NasdaqCM:SABS

US$26.9m

Oncternal Therapeutics

NasdaqCM:ONCT

US$22.8m

vTv Therapeutics

NasdaqCM:VTVT

US$51.2m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Inhibikase Therapeutics
과거 주가
현재 주가	US$1.21
52주 최고치	US$3.82
52주 최저치	US$0.79
베타	1.41
11개월 변경	-33.15%
3개월 변경 사항	-43.98%
1년 변경 사항	-66.48%
33년 변화	-92.80%
5년 변화	n/a
IPO 이후 변화	-97.96%

최근 뉴스 및 업데이트

Recent updates

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Apr 06

Inhibikase Therapeutics prices stock offering at $3

Jun 16

주주 수익률

	IKT	US Biotechs	US 마켓
7D	-13.6%	-0.7%	0.04%
1Y	-66.5%	10.0%	20.7%

수익률 대 산업: IKT 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: IKT 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is IKT's price volatile compared to industry and market?
IKT volatility
IKT Average Weekly Movement	18.0%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.8%

안정적인 주가: IKT 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: IKT 의 주간 변동성( 18% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2008	9	Milton Werner	www.inhibikase.com

임상 단계의 제약 회사인 인히비카제 테라퓨틱스(Inhibikase Therapeutics, Inc.)는 파킨슨병 및 관련 질환 치료제를 개발하는 회사입니다. 주요 제품 후보로는 비수용체 아벨슨 티로신 키나제 억제제인 IkT-148009가 있으며, 파킨슨병 및 위장관 치료를 위한 임상 2a상 시험을 진행 중입니다. 또한 이 회사는 안정기 만성 골수성 백혈병 치료를 위한 항암제 이매티닙 메실산염의 전구 약물인 IkT-001Pro를 개발하고 있습니다.

Inhibikase Therapeutics, Inc. 기본 사항 요약

Inhibikase Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
IKT 기본 통계
시가총액	US$8.73m
수익(TTM)	-US$19.20m
수익(TTM)	US$195.98k

44.6x

P/S 비율

-0.5x

P/E 비율

IKT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
IKT 손익 계산서(TTM)
수익	US$195.98k
수익 비용	US$13.52m
총 이익	-US$13.32m
기타 비용	US$5.88m
수익	-US$19.20m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.66
총 마진	-6,796.37%
순이익 마진	-9,797.30%
부채/자본 비율	4.1%

IKT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

IKT 주식 개요

보상

위험 분석

Inhibikase Therapeutics, Inc. 경쟁사

NasdaqCM:LGVN

US$10.2m

NasdaqCM:SABS

US$26.9m

NasdaqCM:ONCT

US$22.8m

NasdaqCM:VTVT

US$51.2m

가격 내역 및 성능

최근 뉴스 및 업데이트

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

First quarter 2024 earnings released: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Recent updates

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

First quarter 2024 earnings released: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

New major risk - Market cap size

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Full year 2023 earnings: EPS misses analyst expectations

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.

New major risk - Share price stability

Consensus revenue estimates increase by 44%

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc. Provides Update on Development Programs

Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Third quarter 2023 earnings released: US$0.86 loss per share (vs US$1.07 loss in 3Q 2022)

Inhibikase Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib

Consensus revenue estimates increase by 178%, EPS downgraded

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro

New major risk - Financial position

Second quarter 2023 earnings released: US$1.11 loss per share (vs US$1.10 loss in 2Q 2022)

Inhibikase Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces 1-For-6 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Inhibikase Therapeutics, Inc. Initiates Medical and Patient Awareness Campaign for Its Phase 2 '201' Trial Evaluating It-148009 in Parkinson's Disease

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022)

Inhibikase Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

Inhibikase Therapeutics, Inc. announced that it expects to receive $4.199512 million in funding

Inhibikase Therapeutics Announces Publication Demonstrating Potential for C-Abl as A Key Therapeutic Target in Parkinson's Disease and Related Disorders

Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Inhibikase Therapeutics, Inc. Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics, Inc. Provides Update to FDA Clinical Hold of IkT-148009 Programs

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.18 loss in 3Q 2021)

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Inhibikase Therapeutics, Inc Announces FDA Clinical Hold on IkT-148009 Programs

High number of new and inexperienced directors

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Executive Changes

Inhibikase Therapeutics, Inc Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia

Inhibikase Therapeutics, Inc. Doses First Patient in Its Phase 2a '201' Clinical Trial of IKT-148009 to Treat Parkinson's Disease

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Inhibikase Therapeutics, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Inhibikase Therapeutics Receives a Letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.26 loss in 1Q 2021)

Inhibikase Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Full year 2021 earnings released: US$0.81 loss per share (vs US$0.35 loss in FY 2020)